Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 4
2005 4
2006 8
2007 3
2008 3
2009 4
2010 9
2011 8
2012 8
2013 13
2014 16
2015 24
2016 22
2017 25
2018 36
2019 46
2020 45
2021 52
2022 62
2023 45
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

401 results

Results by year

Filters applied: . Clear all
Page 1
Genetic and phenotypic profiling of single living circulating tumor cells from patients with microfluidics.
Dong Z, Wang Y, Xu G, Liu B, Wang Y, Reboud J, Jajesniak P, Yan S, Ma P, Liu F, Zhou Y, Jin Z, Yang K, Huang Z, Zhuo M, Jia B, Fang J, Zhang P, Wu N, Yang M, Cooper JM, Chang L. Dong Z, et al. Among authors: fang j. Proc Natl Acad Sci U S A. 2024 May 7;121(19):e2315168121. doi: 10.1073/pnas.2315168121. Epub 2024 Apr 29. Proc Natl Acad Sci U S A. 2024. PMID: 38683997
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC, Stojanovic G, Jove M, Rich P, Andric ZG, Wu YL, Rudin CM, Chen H, Zhang L, Yeung S, Benzaghou F, Paz-Ares L, Bunn PA; RESILIENT Trial Investigators. Spigel DR, et al. J Clin Oncol. 2024 Apr 22:JCO2302110. doi: 10.1200/JCO.23.02110. Online ahead of print. J Clin Oncol. 2024. PMID: 38648575
JUNO high purity nitrogen plant.
Ling X, Yu B, Hou Z, Hu T, Zhou L, Yan Y, Zhu Z, Cai X, Ding Y, Fang J, Shao J, Sun L, Sun X, Xie Y, Qi X, Zhang H. Ling X, et al. Among authors: fang j. Appl Radiat Isot. 2024 Jun;208:111305. doi: 10.1016/j.apradiso.2024.111305. Epub 2024 Mar 21. Appl Radiat Isot. 2024. PMID: 38537447
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Zheng J, Wang T, Yang Y, Huang J, Feng J, Zhuang W, Chen J, Zhao J, Zhong W, Zhao Y, Zhang Y, Song Y, Hu Y, Yu Z, Gong Y, Chen Y, Ye F, Zhang S, Cao L, Fan Y, Wu G, Guo Y, Zhou C, Ma K, Fang J, Feng W, Liu Y, Zheng Z, Li G, Wang H, Cang S, Wu N, Song W, Liu X, Zhao S, Ding L, Selvaggi G, Wang Y, Xiao S, Wang Q, Shen Z, Zhou J, Zhou J, Zhang L. Zheng J, et al. Among authors: fang j. Cancer Commun (Lond). 2024 Apr;44(4):455-468. doi: 10.1002/cac2.12524. Epub 2024 Feb 29. Cancer Commun (Lond). 2024. PMID: 38421881 Free PMC article. Clinical Trial.
Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer.
Zhang P, Ma M, Nie J, Dai L, Hu W, Zhang J, Wu D, Chen X, Ma X, Tian G, Han S, Long J, Wang Y, Zhang Z, Hao Q, Fang J. Zhang P, et al. Among authors: fang j. Heliyon. 2024 Feb 11;10(4):e26026. doi: 10.1016/j.heliyon.2024.e26026. eCollection 2024 Feb 29. Heliyon. 2024. PMID: 38390071 Free PMC article.
401 results